Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Esteve Quimica
Deal Size : Undisclosed
Deal Type : Acquisition
ESTEVE to Acquire Medicine to Treat Medullary Thyroid Cancer
Details : Esteve will acquire Caprelsa (vandetanib) rights in more than 50 countries, a treatment used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer.
Product Name : Caprelsa
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 30, 2025
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Esteve Quimica
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
Details : Vandetanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thyroid Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 13, 2013
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vandetanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Thyroid cancer, medullary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2012
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vandetanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thyroid cancer, medullary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2012
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Details : Vandetanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Thyroid Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2011
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vandetanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thyroid cancer, medullary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2011
Lead Product(s) : VANDETANIB
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
